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Abstract
Background: Clinicians mediate access to closed-loop technology for people with diabetes. Consequently, their
attitudes regarding appropriate levels of closed-loop usage will play a key role in future adoption processes.
This study aimed to explore clinician attitudes toward future mainstream closed-loop usage in England.
Materials and Methods: We conducted 36 semistructured interviews with clinicians from a range of profes-
sional backgrounds working in outpatient clinics in England. Interview topics included clinicians’ views on
future pathways for closed-loop use and attitudes toward the predictability of users’ technology experiences, a
key factor in eligibility decision making. We analyzed transcripts using thematic and framework approaches.
Results: Clinicians exhibited a range of opinions regarding future eligibility for closed-loop technology. We
identified three key strands of clinician opinion, envisaging (1) tighter access for closed loop (n= 10), citing
funding challenges and issues arising from user overconfidence or negative technology attitudes; (2) similar
access to closed loop as for current diabetes technologies (n= 15), on the grounds that future funding and access
pathways will be similar to current arrangements; and (3) wider access for closed-loop technologies (n= 9),
given the potential for significant and widespread benefits arising from closed-loop usage, including down-
stream cost savings alongside improved glycemic control.
Conclusions: Clinicians expressed a range of opinions encompassing continuity with current diabetes tech-
nologies, while others envisaged either tighter or more liberal access for closed-loop systems. To optimize
technology adoption and equitable uptake, future implementation pathways should consider clinician attitudes
toward technology use and access.
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Introduction
Closed-loop (or ‘‘artificial pancreas’’) systems linkwearable continuous glucose monitor (CGM) sensors to
algorithms that process CGM data and issue frequently up-
dated infusion commands to single-hormone (insulin) or
dual-hormone (insulin and glucagon) pumps.1 Multiple
closed-loop systems have been developed, and their safety
and efficacy have been evaluated in numerous studies, gen-
erating impressive results in terms of glycemic control.2,3
Commercially available systems such as the FDA-approved
Medtronic 670G, a hybrid system requiring user input for
tasks such as prandial bolusing, raise the possibility of
widespread access to closed-loop technology.4 In resource-
constrained settings, however, financial pressures may gen-
erate incentives for limiting access,5 particularly if the greater
complexity of closed-loop systems requires additional health
service expenditure on training, staffing, and logistical sup-
port. In addition, recent data showing high levels of attrition
in 670G usage in the USA highlight the user-centered chal-
lenges that may arise with widespread hybrid closed-loop
usage.6 While highly specific to 670G systems, these data
1THIS Institute (The Healthcare Improvement Studies Institute), University of Cambridge, Cambridge, United Kingdom.
2Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom.
3Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
4Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
5Department of Women and Children’s Health, King’s College London, London, United Kingdom.
ª Conor Farrington, et al., 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the
Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited.
DIABETES TECHNOLOGY & THERAPEUTICS
Volume 22, Number 5, 2020
Mary Ann Liebert, Inc.
DOI: 10.1089/dia.2019.0380
1
nevertheless echo previous psychosocial research reporting
burdens as well as benefits for closed-loop users.7 While
670G and (increasingly) home-made closed-loop systems are
used by growing numbers of users, national and international
eligibility guidelines have yet to be formulated.8 Conse-
quently, while the automated nature of closed-loop tech-
nology promises improved control for people with type 1
diabetes, debate continues regarding appropriate levels of
closed-loop usage in mainstream care.
Clinician attitudes are currently a neglected aspect of this
debate, yet evidence from implementation research shows
that technology adoption is more successful when a range of
stakeholder perspectives are taken into account.9 A recent
review, for example, emphasizes the potential for clinicians
to both enable and hinder technology adoption, stating that,
‘‘[a]cceptance [of new technologies] by professional staff
may be the single most important determinant of whether a
new technology-supported service succeeds or fails at a local
level.’’9
This importance arises by clinicians’ privileged decision-
making positions, from which they adjudicate whether indi-
viduals are legitimate candidates for specific treatments or
technologies.10 In the specific context of diabetes technology,
researchers have begun to explore how clinicians mediate
access to currently available devices such as pumps, CGM,
and sensor-augmented pumps (including low glucose sus-
pend systems), for example, by supplementing frequently
ambiguous formal criteria in national guidelines with infor-
mal criteria based on clinical experience.11 A study of dia-
betes specialist nurses and dieticians involved in the
REPOSE trial found that clinicians had strong, yet often in-
accurate beliefs regarding the suitability of individuals for
pump use.12 While these predictions about the likely char-
acter of users’ future technology experiences were overrid-
den in REPOSE by randomization to pump or multiple daily
injection, participating clinicians acknowledged that their
views about individuals’ suitability for specific devices did
influence decision making about technology eligibility out-
side trial conditions.
While previous researchers have explored clinician atti-
tudes to other aspects of technology in type 1 diabetes care,
little is known on clinician views about access to closed-loop
technology.13–17 To address this gap, we undertook a quali-
tative study of clinician attitudes in England, guided by the
following research question: what are clinicians’ attitudes
toward user eligibility for future closed-loop systems in
mainstream care in England?
Research Design and Methods
Design
Qualitative study using semistructured interviews.
Setting
We carried out 36 interviews with clinicians working at five
hospital diabetes outpatient clinics serving adult (two clinics),
pregnant (two clinics), and pediatric (one clinic) populations
with type 1 diabetes in three hospitals in England, chosen to
provide a range of geographical and socioeconomic contexts.
Hospital 1 (pregnancy and pediatric clinics) is a large teaching
hospital in an affluent area in the East of England; Hospital 2
(pregnancy and adult clinics) is a teaching hospital in a less
affluent area, situated in East Anglia; and Hospital 3 (adult
clinic) is a large teaching hospital in the north of England.
A sixth clinic serving pediatric patients in Hospital 3 declined
to participate in the study. All three hospitals had been in-
volved in diabetes technology trials.
Participant recruitment
Following ethics approval, we received permission from
local NHS Trusts to approach members of outpatient clinic
staff for interview. We contacted potential participants by
email, with a participant information sheet and consent form,
and offered all participants an interview in person or by
telephone at a convenient time, date, and place. In addition,
we used a snowball sampling approach to identify additional
staff for interview, asking participants for recommendations
of other suitable candidates. We attempted to interview cli-
nicians from a range of professional backgrounds (see
Table 1 for participant characteristics).
Participants are identified using the following naming
convention: hospital number/clinic population/profession/
number of interviewees within clinic. Abbreviations for
clinic population and profession are given in parenthesis in
relevant headings of Table 1.
Data collection
[Name removed for peer review] conducted interviews in
person (n = 29) and by telephone (n = 7), between October
2017 and June 2018. All participants gave informed consent
to participate and to allow digital recording and verbatim
transcription of interviews by a trusted agency. We used a
semistructured topic guide informed by relevant literature
and designed to allow for the exploration of a range of issues
Table 1. Participant Characteristics
Professional background
General
medicine/
endocrinology
(PHYS)
Nursing
(NU)
Dietetics
(DI)
Obstetrics
(OBS)
Midwifery
(MW)
Anesthesiology
(ANAEST)
Psychology
(PSYCH) TotalLocation
Outpatient
clinic
population
Hospital 1 Pregnancy (PR) 1 2 2 2 1 / / 8
Pediatric (PA) 6 2 3 / / / 1 12
Hospital 2 Pregnancy (PR) 2 3 1 1 1 1 / 9
Adult (AD) 4 / / / / / / 4
Hospital 3 Adult (AD) 2 1 / / / / / 3
Total 15 8 6 3 2 1 1 36
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relevant to diabetes technology. In the context of guidelines,
our topic guide focused on technology access pathways and
on clinician attitudes to the predictability of technology use
by people with diabetes (see Supplementary Data for detailed
topic guide). Interviews lasted between 28 and 73 min, with
an average time of 47.5 min.
Data analysis
We analyzed the data using a combination of thematic and
framework analysis approaches. Initial coding of interview
transcripts took place alongside data collection to identify
key themes and generate a provisional coding structure. We
then utilized this provisional structure to undertake an initial
thematic analysis, using QSR NVivo (Version 12) software
(see Supplementary Table S1 for details of coding structure).
Our thematic analysis approach used a six-stage inductive
approach: familiarization with the data; generating initial
codes; searching for themes; reviewing themes; defining and
naming themes; and producing an overall analysis.17
We then supplemented our thematic analysis with frame-
work analysis, a more deductive method involving the use of
a matrix with cells into which summary qualitative data are
entered by category (rows) and cases (columns).18 This al-
lowed us to identify and explore patterns (categories) that cut
across individual clinician attitudes (cases). For this study,
we focused on two key areas: clinician expectations regard-
ing future access pathways to closed loop and clinician per-
spectives on the predictability of technology use by people
with diabetes, including closed loop alongside older tech-
nologies such as pumps and CGM. C.F. conducted the ana-
lyses, later discussing them with H.R.M. and R.H. to establish
reader agreement.
Results
Our findings are presented in three main sections, relating,
respectively, to clinician viewpoints suggesting that: (1) ac-
cess to closed loop will be tighter than eligibility for currently
available technologies (n = 10); (2) eligibility for closed loop
will be similar to eligibility for currently available CGM and
CSII technologies (n= 14); and (3) eligibility will be wider
than eligibility for currently available technologies (n = 9).
Clinicians invoked a range of reasons to support each view, as
indicated by subheadings in each section.
In terms of professions, most physicians expected looser
access arrangements and most nurses mostly expected looser
or similar access arrangements; otherwise, no clear patterns
emerged across different professions. Similarly, no clear
patterns emerged across different hospitals or clinics serving
different populations.
Tighter eligibility constraints for closed loop
Several interviewees (n= 10) recommended limiting eligi-
bility to users who will clearly benefit from closed-loop
technology, raising the possibility of stricter constraints than
those currently in place for pumps and CGM. Clinicians varied
in the kinds of reasons they gave for expressing this point of
view, including user-centered technical challenges, psycho-
logical impacts, unrealistic expectations, and funding issues.
Technical challenges. Some clinicians framed tighter el-
igibility constraints in terms of the greater technical challenges
and user input required for successful operation of closed-loop
systems, thus reserving access for highly motivated pro-
technology users. One physician, for example, described
closed-loop technology as a ‘‘step higher’’ and therefore re-
quiring ‘‘more work’’ than existing devices (1/PA/PHYS/2),
while a nurse in the same pediatric clinic suggested that ‘‘some
families may struggle with the whole technology side of
things. [A] lot of families [of children with diabetes] don’t
get on with technology’’ (1/PA/PHYS/5). In this context, cli-
nicians expressed concerns that operation of closed-loop sys-
tems without, for example, careful manual premeal bolusing
could lead to suboptimal outcomes for users. One physician
described this scenario with a motoring analogy: ‘‘we’re giv-
ing you [the user] a Ferrari, you’re choosing not to get out of
second gear’’ (2/AD/PHYS/1).
Psychological impacts. Other clinicians worried about
the potential impacts of closed-loop technology on some
users’ psychological status, describing this as ‘‘the biggest
unknown’’ and asking if these new systems might make users
‘‘more anxious’’ (3/AD/PHYS/1) as a result of surrendering
control. As one physician put it, ‘‘[T]here are lots of people
that will. say that they prefer to have control, i.e., do their
own injections. They don’t want to give that control over to
an inanimate object’’ (2/PR/PHYS/2).
Unrealistic expectations. Interviewees also expressed
psychological concerns regarding protechnology users, sug-
gesting that some users might place undue confidence in
closed-loop systems and/or engage less proactively in self-
care. One physician described this concern in terms of those
who might ‘‘plug [the closed-loop system] in and forget,
[thinking] you don’t have to do anything else, [whereas] you
probably need to do a lot more than you would normally be
doing’’ (2/AD/PHYS/2). Similarly, a psychologist working
in a pediatric clinic highlighted the danger of unrealistic
expectations: ‘‘[some families] just think this device is just
going to do everything and actually that’s not the case’’ (1/
PA/PSYCH/12). In such contexts, clinicians expressed con-
cern that some protechnology users may not notice technical
glitches, with potentially negative impacts on their health:
‘‘you need to question it, you need to recognize that it might
not be calibrated. that’s the worry [with] the [users] who
just go, ‘skippety skip, off we go’’’ (1/PA/PHYS/6).
Funding challenges. A number of clinicians raised is-
sues regarding funding, which they saw as likely to place
tight limits on future closed-loop access. Specifically, some
feared greater restrictions on closed-loop usage than pumps
because of the higher cost of newer systems: ‘‘I’m pretty
sure it’ll only be given to a very small percentage of [pa-
tients]’’ (1/PR/DI/11). Similarly, one nurse stated that ‘‘we
need more, other criteria to define who needs to be [using
closed loop]. because mainly I think it will be an expensive
system. And it’s more complicated probably than the
pump or the [CGM] sensor per se’’ (1/PA/NU/2). One
physician expressed the view that future National Institute
for Health and Care Excellence (NICE) guidelines regarding
closed-loop access are likely to be stringent:
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You’re talking about what’s going to be an expensive gad-
get.I guess in future if it comes in the UK. it won’t be very
lenient criteria [but rather] very stringent criteria, for example
life-threatening hypoglycaemia.
2/AD/PHYS/1
Similar eligibility constraints for closed loop
While some clinicians advanced the view that future ac-
cess to closed loop may need to be limited from both user
welfare and funding perspectives, a substantial number
(n = 15) thought that levels and means of access would reflect
current access arrangements for pumps and CGM. Clinicians
in this group advanced a range of reasons in support of this
perspective, including organizational continuity, funding
challenges, user engagement, and challenges surrounding
predictions of user technology experience.
Organizational continuity. Clinicians in this group em-
phasized that future users will continue to gain access to diabetes
technology through health service pathways similar to those
currently used for technologies such as pumps and CGM, fea-
turing ‘‘multidisciplinary team discussions’’ involving clini-
cians from a range of backgrounds and guided by clinic
organizational structures, NICE eligibility criteria, and local
funding arrangements (1/PA/DI/10). One dietician stated that
future access ‘‘will probably be quite similar to how we [discuss]
pumps. Obviously it won’t be suitable for everyone, there will
definitely need to be some criteria we would use’’ (1/PR/DI/5).
In the absence of published guidelines, clinicians expressed
uncertainty regarding the precise content of future eligibility
criteria; one dietician suggested for instance that ‘‘I’m guessing
there’ll be criteria that need to be met. I don’t really know yet,
so I guess we’ll just have to wait and see’’ (1/PA/DI/10).
Clinicians also envisaged similar accessibility decision
making within the context of these organizational continui-
ties. One physician, for example, envisaged prioritization of
selected users for closed-loop usage in future, as currently
occurs when initiating pump therapy: ‘‘Anything new, we do
tend to select patients at the start, so when we started pumps,
we didn’t start with our high-risk patients, we started with our
incredibly reliable patients’’ (1/PR/PHYS/1).
Funding challenges. A number of clinicians thought
closed-loop access would be limited by funding in a similar
way to current use of pumps and CGM. As one nurse put it: ‘‘I
think it would be quite similar to now, in the respect that.
there is always going to be financial restraints, [so] we are
going to have to have these discussions. [about] who is
eligible for them’’ (2/PR/NU/6).
User engagement. Clinicians in this group also empha-
sized continuities between access to closed loop and access to
previous technologies in terms of the importance of user
engagement and motivation as factors in gaining access to
diabetes technology. Some clinicians suggested that users’
engagement in self-care and technology use would function
as a criterion for closed-loop access, as it currently does for
pumps and CGM:
The people who might struggle with it. will just put the
system on and ignore it and . they won’t test, they won’t
calibrate it. [B]ut if they’re not calibrated, they won’t be
given CGM, [and] they can’t have the closed-loop system
[either]. So I think it might police itself, really.
3/AD/NU/2
Challenges in predicting user technology experience.
Clinicians drew on past experience with pump and CGM
technologies to emphasize the difficulty of predicting whe-
ther individual users would react positively or otherwise to
closed-loop use, which is a key constraining factor in current
access decisions. One physician remarked, for example, that
‘‘I think you’ve got a sense who’s going to do well or not, but
sometimes patients prove you wrong. maybe ten per cent
[or] twenty per cent [of the time]’’ (2/AD/PHYS/4). Simi-
larly, a midwife in a different clinic stated that ‘‘there’s that
20 per cent that, for whatever reason, whether it’s us or them
or their diabetes. it’s just not going to work for them’’
(1/PR/MW/8).
Relatedly, some clinicians also highlighted the ever-
present possibility of being surprised by users’ technology
experience, further emphasizing the constraints involved in
making access decisions based on predictions of technology
experience. One physician expressed surprise at the positive
experiences of disadvantaged people and, by comparison, the
negative experiences of more advantaged people (such as
clinicians themselves): ‘‘I’m sometimes surprised at the
healthcare professionals [with diabetes] who don’t seem to
take it very seriously [and who are] very casual and relaxed in
their self-management’’ (2/PR/PHYS/4). Another clinician
supported this view, stating: ‘‘there’s always surprises in
terms of user technology outcomes’’ (1/PA/PHYS/6), while
another stressed that users’ age was not, as often assumed, an
infallible guide to success: ‘‘I think maybe the assumption is
if somebody’s younger. that they’d be okay with [tech-
nology] but sometimes it’s the reverse, so you can never quite
tell’’ (2/PR/PHYS/2). In addition, others highlighted the
possibility of technology itself triggering changes in levels of
user engagement. Interviewees saw this as a complicating
factor in attempts to predict further use: as one nurse put it,
‘‘until we start using [closed-loop technology] I wouldn’t
really know who would be good with it and who wouldn’t’’
(3/AD/NU/2).
Looser eligibility constraints for closed loop
A number of clinicians (n = 9) hoped for wider usage for
closed-loop systems than for currently available technolo-
gies. They based this perspective on a range of consider-
ations, including expectations of potentially widespread
benefits from closed-loop usage, the likelihood of liberal
access guidelines, the potential for cost savings arising from
closed-loop usage, and (in opposition to clinicians cited
above) the unpredictability of user technology experience.
Widespread benefits. One physician described a vision
of closed-loop systems as potentially benefitting up to 80% of
people with type 1 diabetes:
I think there’ll always be a group of patients, like 20/30 per
cent, who’ll be able to get better control by themselves than
they would do with closed loop, but what I see closed loop
doing is getting a larger range.a broader range of people to
an acceptable level.
2/PR/PHYS/4
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Another physician in the same clinic described closed-
loop systems as ‘‘particularly good for patients who aren’t
very motivated. because the difficult stuff will be done for
them’’ (2/PR/PHYS/1). Others clinicians envisaged a less
universal, but still generous set of parameters; one physician
stated, for instance, that ‘‘anyone whose. control is poor in
spite of clinical optimization, and anyone who’s got a fear
[of] or. significant problems with hypoglycemia should be
eligible for closed loop’’ (2/PR/PHYS/1).
Liberal access guidelines. In this light, a number of cli-
nicians emphasized the potential for liberal eligibility
guidelines for closed-loop systems. One midwife described
the basis of a liberal access policy on pragmatic and evi-
dential grounds: ‘‘[I]f we’ve got the reassurance that it works,
then why would you be selective?’’ (1/PR/MW/8). Another
clinician advocated universal usage if funding and wear-
ability constraints could be overcome:
[closed-loop systems] will be good for anyone with type 1
diabetes. if money was not an issue then I think anyone
would be good for it. I can’t for the moment think of someone
who might not want it, apart from people who might not like to
be attached to something all the time.
2/PR/DI/3
Some interviewees framed a liberal approach to access in
terms of ethical responsibility, for example:
[O]nce closed-loop technology really takes off, we won’t have
the same kind of discussions [as with pumps and CGM]. [I]f
that’s the therapy that’s proven to the best for everyone, then it
would be wrong to deny that to people.
1/PA/NU/7
Cost savings. In opposition to the fear (mentioned
above) that high costs could limit access, some clinicians
raised the possibility that improved glycemic control offered
by closed-loop systems could help patients to avoid com-
plications, which in turn would reduce health care spending.
One midwife stated that ‘‘when you think of the complica-
tions, it would be a lot cheaper to [use closed-loop systems
than not]’’ (2/PR/MW/7). From this perspective, interview-
ees saw high short-term costs as offset by long-term savings,
again supporting a generous access and eligibility policy.
Beyond predictability. While some clinicians (as dis-
cussed above) saw the unpredictability of future technology
outcomes as a reason to be cautious regarding user eligibility,
others were inclined to be more adventurous in terms of fu-
ture access, precisely because of the difficulty of predicting
future technology use. One physician in a pregnancy clinic
described this approach as follows: ‘‘I think it is always very
hard to tell who.will do well and who won’t. So.my own
preference is to let people have a go and then see how they
go’’ (2/PR/PHYS/4). Others seemed to suggest that predict-
ability would be less important in the closed-loop context
because of the potentially transformative impacts of closed-
loop usage on users themselves: ‘‘any concerns that people
have will disappear very quickly, once they get the faith in the
technology’’ (3/AD/PHYS/3). Another clinician in a preg-
nancy clinic stated a preference for wide use regardless of
predictability, since ‘‘closed loop can really help achieve
[better control]’’ and therefore ‘‘we will want all of our
women on it if it is available’’ (1/PR/DI/2).
Conclusions
Our interviewees expressed a wide range of opinions re-
garding the question of who should access closed-loop
technology. A group of 15 clinicians emphasized continuities
between closed loop and preceding technologies such as
pumps and CGMs. Specifically, these interviewees high-
lighted the continuing need for users to gain access to future
technology through similar health service pathways as are
currently in place, in addition to the ongoing need to take
account of funding limitations, allow for unpredictable
technology experiences, and prioritize access for more highly
motivated users.
A larger group of 19 clinicians thought that future access
arrangements would differ for closed-loop technology, but
were divided as to whether access should be tighter (n = 10) or
more liberal (n = 9) compared with pumps and CGM. Those
who expected tighter restrictions mentioned a range of con-
siderations, such that advanced closed-loop technology re-
quired motivated and protechnology users, but also that
protechnology users who placed excessive trust in closed
loop could suffer suboptimal outcomes as a result. These
clinicians also suggested that higher costs associated with
closed-loop systems could lead to stringent eligibility
guidelines in England. Those who envisaged more liberal
access, by contrast, thought that long-term benefits of wide-
spread closed-loop usage (e.g., reduced complications) would
outweigh initial investment in closed-loop provision. These
interviewees saw widespread usage as justified by factors,
including the clinical benefits of closed-loop usage, ethical
duties to provide the best possible care, and the challenges of
predicting technology use. If up to 80% of the type 1 diabetes
population would benefit from closed-loop usage, as one
physician suggested, it becomes less vital to predict tech-
nology outcomes for an individual.
While clinicians generally aligned themselves with per-
spectives envisaging tighter, similar, or looser access to
future closed-loop systems, they varied in terms of the kinds
of reasons they gave in support of these views. In each
group, interviewees variously mentioned technical, psy-
chological, financial, and (in the ‘‘similar’’ access group)
organizational factors. In addition, clinicians who discussed
certain factors—for example, psychological factors in the
‘‘tighter’’ group—did not always emphasize the same spe-
cific factors. Consequently, our interviewees demonstrated
considerable diversity of opinion within, as well as between,
the three main groups identified in our analysis.
Our study advances beyond previous work primarily in its
attempt to elicit and explore clinician rather than user per-
spectives on closed-loop technology, and in its identification
of the wide range of clinician opinion regarding future eli-
gibility for closed-loop usage. Some of these attitudes align
with previous research on user experience of closed-loop
technology, and, in particular, with studies emphasizing a
mix of potential benefits and burdens for users of closed-loop
systems.7 Yet our interviewees also provided informative
clinician perspectives on a number of further topics, includ-
ing issues of short- and long-term funding, predictability of
user technology experience, ethical duties of care, and the
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need to establish clear expectations from the outset.19 Most
importantly, our findings demonstrate that clinicians hold
widely differing views regarding future eligibility for closed-
loop technology, encompassing three broad groups with
tighter, similar, and looser access constraints, respectively.
The range of opinions expressed suggests that closed loop has
yet to attain a clear and settled ‘‘technology identity,’’ or a
widely shared understanding of closed-loop technology.20 In
the absence of such an identity for closed-loop systems, there
is a risk of clinicians drawing on informal criteria to limit or
expand access, as with current insulin pumps and CGM
technologies.11–12 Specifically, our findings regarding prior-
itized technology access for highly motivated users raise
concerns regarding clinician gatekeeping in the closed-loop
context. Such gatekeeping could lead to potentially unwar-
ranted restrictions on access to closed-loop systems, for ex-
ample, if clinicians are unduly pessimistic regarding future
closed-loop outcomes for users seen as ‘‘unmotivated.’’11
Strengths of our study include in-depth interviews with
clinicians from different backgrounds serving a range of
populations, and with varied experience of closed-loop
technology. Our study is limited by uneven numbers of in-
terviewees serving pregnant (n = 17), pediatric (n = 12), and
adult (n = 7) populations, and by the dominance of physicians
(n = 15) as opposed to professions such as nursing (n = 8) and
dietetics (n= 6). Self-selection bias is possible insofar as
clinicians who agreed to participate may have been positively
disposed toward closed-loop technology and/or participation
in research projects. The geographical spread of our inter-
viewees was limited by the low number of clinicians re-
cruited at Hospital 3 (n = 3), and because a second clinic at
Hospital 3, serving the pediatric population, declined to
participate in the study. While we aimed to recruit the widest
possible range of participants, it is possible that clinicians
working in other contexts may have different views regarding
the introduction of closed-loop technologies into mainstream
care, especially in hospitals without diabetes technology trial
experience and/or nonteaching hospitals. Future research
could investigate the views of clinicians working in a wider
variety of geographical settings (including settings beyond
the United Kingdom), and serving a wider range of popula-
tions, including those whose cultural beliefs may present
further barriers to closed-loop adoption.15 Finally, our study
is also limited by the rapid pace of development in the field of
diabetes technology, which could lead to different findings if
our study was to be repeated in the future, at a time when, for
example, people with type 1 diabetes may make widespread
use of home-made closed-loop systems.21 Our interviewees’
concerns regarding calibration, for instance, may be less
relevant to future systems.
In conclusion, clinicians expressed a range of opinions
regarding eligibility for future closed-loop technology in
England. Some emphasized continuity with preceding tech-
nologies such as insulin pumps, while others expected either
tighter or more liberal access arrangements for closed-loop
systems. Since clinicians mediate user access to technology,
these varied attitudes may exert substantial impact on future
technology use, especially if clinicians are excessively opti-
mistic or pessimistic regarding likely outcomes of closed-
loop usage. To optimize technology adoption and equitable
uptake, future implementation pathways should consider
clinician attitudes toward technology use and access, in ad-
dition to the need for tailored education programs to build
clinician knowledge of new diabetes technologies. In this
context, one possible approach could be to undertake for-
mative consultation with clinicians (alongside other stake-
holders) to develop a settled and widely shared technology
identity for closed-loop systems, and co-design of closed-
loop technology pathways.22
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